BACKGROUND: Newborn animal and @entity1 pilot studies suggest that mild @entity2332 following peripartum @entity519 -ischaemia in newborn @entity1 may reduce neurological sequelae, without adverse effects. OBJECTIVES: To determine whether @entity2332 in encephalopathic asphyxiated newborn @entity1 reduces mortality and long-term @entity245 , without clinically important side effects. SEARCH STRATEGY: The standard search strategy of the Neonatal Review Group as outlined in the Cochrane Library (Issue 2, 2003) was used. Randomised controlled trials evaluating @entity2332 in term newborns with @entity519 ischaemic @entity75 were identified by searching the Oxford Database of Perinatal Trials, the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library Issue Issue 2, 2003), MEDLINE (1966 to July 2003), previous reviews including cross-references, abstracts, conferences, symposia proceedings, expert informants and journal hand searching. SELECTION CRITERIA: Randomised controlled trials comparing the use of @entity2332 with normothermia in encephalopathic newborn @entity1 with evidence of peripartum @entity1763 and without recognisable major @entity154 were included. The primary outcome measure was @entity204 or long-term major @entity245 . Other outcomes included adverse effects of cooling and 'early' indicators of neurodevelopmental outcome. DATA COLLECTION AND ANALYSIS: Three reviewers independently selected, assessed the quality of and extracted data from the included studies. Authors were contacted for further information. Meta-analyses were performed using relative risk and risk difference for dichotomous data, and weighted mean difference for continuous data with 95% confidence intervals. MAIN RESULTS: Two randomised controlled trials were included in this review, comprising 50 term @entity1 with moderate/ severe @entity75 and evidence of intrapartum @entity1763 . There was no significant effect of @entity2332 on the combined outcome of @entity204 or major @entity245 in survivors followed. No adverse effects of @entity2332 on short term medical outcomes or on some 'early' indicators of neurodevelopmental outcome were detected. REVIEWER'S CONCLUSIONS: Although two small randomised controlled trials demonstrated neither evidence of benefit or harm, current evidence is inadequate to assess either safety or efficacy of @entity2332 in newborn @entity1 with @entity519 ischaemic @entity75 . @entity2332 for encephalopathic asphyxiated newborn @entity1 should be further evaluated in well designed randomised controlled trials.

Cooling for newborns with XXXX ischaemic @entity75 .

@entity1 :: ('9606', 'Species') :: ['human', 'infants'] @entity154 :: ('MESH:D000013', 'Disease') :: ['congenital anomalies'] @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy'] @entity245 :: ('MESH:D002658', 'Disease') :: ['neurodevelopmental disability'] @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxic', 'hypoxia'] @entity1763 :: ('MESH:D001237', 'Disease') :: ['asphyxia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity2332 :: ('MESH:D007035', 'Disease') :: ['Therapeutic hypothermia', 'hypothermia', 'therapeutic hypothermia']
@entity519 :: (MESH:D000860,Disease) :: ['hypoxic']
